Oncternal Therapeutics Company Overview
About Oncternal Therapeutics
Oncternal Therapeutics (NASDAQ:ONCT) is a biopharmaceutical company dedicated to developing innovative therapies for cancer treatment with a focus on addressing unmet medical needs. With an aim to extend and enhance the lives of patients suffering from cancer, Oncternal is currently engaging in several promising projects, including the development of targeted therapies that leverage the latest advancements in oncology research. The company's pipeline showcases a diverse range of investigational drugs, each designed to target specific mechanisms involved in the growth and spread of cancerous cells. Objectives at Oncternal include progressing clinical trials to eventually bring new, effective cancer treatments to market, improving patient outcomes, and establishing partnerships to enhance research and development capabilities.
Snapshot
Operations
Produtos e/ou serviços de Oncternal Therapeutics
- Cirmtuzumab, a ROR1 monoclonal antibody targeting chronic lymphocytic leukemia, mantle cell lymphoma, and breast cancer.
- TK216, a small molecule ETS-family transcription factor inhibitor for Ewing sarcoma.
- ROR1 CAR-T therapies, focusing on innovative chimeric antigen receptor T-cell therapies for solid tumors and hematologic cancers.
- Zilovertamab vedotin, an antibody-drug conjugate targeting ROR1-expressing tumors.
- ONCT-216, targeting B-cell malignancies and certain solid tumors with a focus on developing next-generation inhibitors.
- Collaborative research to identify and advance novel cancer therapeutic candidates, emphasizing partnerships with academia and industry.
equipe executiva do Oncternal Therapeutics
- Dr. James B. Breitmeyer M.D., Ph.D.President, CEO & Director
- Mr. Richard G. Vincent CPACFO & Treasurer
- Dr. Rajesh Krishnan Ph.D.Chief Technical & Scientific Officer
- Mr. Chase C. Leavitt J.D.General Counsel & Secretary
- Mr. Pablo UrbanejaSenior Vice President of Corporate Development